TABLE 3.
The roles of miR-21-5p in lung disease.
| Author | Disease | Target/pathway | Role | Expression | Reference |
|---|---|---|---|---|---|
| Zhou | NSCLC | — | Biomarker | ↑ | Zhou et al. (2022) |
| Yan | NSCLC | TGF-βI | Induce cell proliferation | ↑ | Yan et al. (2018) |
| Tang | NSCLC | SMAD7 | Boost NSCLC progression | ↑ | Tang et al. (2021) |
| Song | NSCLC | — | Decrease radiosensitivity | ↑ | Song et al. (2017) |
| Wu | HILI | SKP2/Nr2f2/C/EBPα axis | Alleviate HILI | — | Wu et al. (2022) |
| Qi | HILI | MAP2K3 | Reduce cellular apoptosis | — | Qi et al. (2021) |
| Liu | HILI | PGAM5 | Regulate hyperoxia-induced mitophagy and mitochondrial dysfunction | — | Liu et al. (2020) |
| Qin | Hyperoxic acute lung injury | PTEN/AKT | Inhibit apoptosis of AEC II cells | — | Qin et al. (2019) |
| Wang | PF | TGF-β1/SMAD and MAPK/AP-1 signaling pathways | Alleviate PF | — | Wang et al. (2018) |
| Ren | Lung cancer | PTEN, PDCD4, and RECK | Promote lung cancer development | — | Ren et al. (2019) |
| Li | Lung ischemia/reperfusion injury | PTEN and PDCD4 | Alleviate lung ischemia/reperfusion injury | — | Li et al. (2019) |